It GBL1 gene therapy

It GBL1 gene therapy has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Oct 31, 2026: “Virus-based delivery eased obesity or osteoporosis in mice”.

Intervention

1 paper studies it2 findingsUpdated Sep 2, 2026

1 new paper in 30 daysSee all 1

None of its findings points the other way.

1 lab in 1 country

Funder: National Natural Science Foundation of China

Animals1

What did studies of It GBL1 gene therapy find?

Studies of It GBL1 gene therapy measured 2 outcomes; the most studied are osteoporosis (1 study) and obesity (1).

Osteoporosis

downin mice1

1 study

It GBL1 gene therapy decreases osteoporosis in mice.
“adeno-associated virus serotype 9-mediated ITGBL1 supplementation significantly alleviates obesity and/or osteoporosis in HFD-fed mice, OVX mice and systemic ITGBL1-deficient mice.”
AnimalsHFD-fed mice, OVX mice and systemic ITGBL1-deficient mice; obesity and/or osteoporosis modelsadeno-associated virus serotype 9-mediated
Virus-based delivery eased obesity or osteoporosis in mice
Cell death & diseaseSep 2, 2026

Latest

1 paper in 12 months

Cell Death & DiseaseOct 31

Virus-based delivery eased obesity or osteoporosis in mice

Virus-based supplementation of a stem-cell regulator eased obesity, osteoporosis or both across three mouse models.Virus-based supplementation of a stem-cell regulator eased obesity, osteoporosis or both across three mouse models.

Mouse studyOsteoporosis

Paper

It GBL1 gene therapy

What did studies of It GBL1 gene therapy find?

Latest

Virus-based delivery eased obesity or osteoporosis in mice

Related